Inter Pharma PCL
SET:IP
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (12.6), the stock would be worth ฿4.33 (11% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 11.4 | ฿3.9 |
0%
|
| 3-Year Average | 12.6 | ฿4.33 |
+11%
|
| 5-Year Average | 15.5 | ฿5.31 |
+36%
|
| Industry Average | 9.3 | ฿3.18 |
-19%
|
| Country Average | 8.6 | ฿2.95 |
-24%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| TH |
I
|
Inter Pharma PCL
SET:IP
|
2.4B THB | 11.4 | 32.9 | |
| FR |
|
L'Oreal SA
PAR:OR
|
191.5B EUR | 18.9 | 31.2 | |
| UK |
|
Unilever PLC
LSE:ULVR
|
105.2B GBP | 12.4 | 12.7 | |
| IN |
|
Hindustan Unilever Ltd
NSE:HINDUNILVR
|
5T INR | 33.2 | 34.6 | |
| UK |
|
HALEON PLC
LSE:HLN
|
33.2B GBP | 14 | 19.9 | |
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
30.5B USD | 15.7 | -171.3 | |
| DE |
|
Beiersdorf AG
XETRA:BEI
|
17.3B EUR | 8.7 | 18.4 | |
| JP |
|
Kao Corp
TSE:4452
|
2.9T JPY | 10.6 | 23.2 | |
| IN |
|
Godrej Consumer Products Ltd
NSE:GODREJCP
|
1.1T INR | 35.6 | 59.1 | |
| CA |
|
Relevium Technologies Inc
XTSX:RLV
|
12.2B CAD | -6 373.4 | -4 624.4 | |
| IN |
|
Dabur India Ltd
NSE:DABUR
|
814.3B INR | 32.2 | 44.2 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 6.6 |
| Median | 8.6 |
| 70th Percentile | 11.4 |
| Max | 3 584.8 |
Other Multiples
Inter Pharma PCL
Glance View
Inter Pharma PCL is engaged in biopharmaceutical business. The company is headquartered in Bangkok, Bangkok Metropolis. The company went IPO on 2019-11-05. The firm is principally engaged in the importing, manufacturing and distribution of dietary supplement product for humans and animals. The firm provides wellness and anti-aging products, aesthetic innovation products, animal health products and livestock products. Its wellness and anti-aging products include Probac7, Probac10 plus, TS6, Beta Glucan Plus, Pure Krill Oil, Astacurmin and YUUU Cleansing Mousse. Its aesthetic innovation products include Perfectha Complement, Perfectha Derm, Perfectha Deep and Perfectha Subskin. The Company’s animal health products include Dr.Choice Cal-B, Dr.Choice Cardi-B, Petinol, Pet Select Senior, Pet Select Osteoflex and Malaseb Shampoo for dogs and cats. The company also offers pet foods for dogs and cats. Its subsidiaries include Inter Vetta Co., Ltd., Modern Pharma Co., Ltd. and Inter Petrina Co., Ltd.
